26 results (0,16307 seconds)

Show all filters

Brand

Show all

Colour

Size

Show all

Gender

Merchant

Show all

Price (EUR)

Reset filter

Products
From
Shops

Carolina Herrera Very Good Girl Eau De Parfum (Various Sizes)

Carolina Herrera Very Good Girl Eau De Parfum (Various Sizes)

Carolina Herrera Very Good Girl Eau De Parfum (Various Sizes) The iconic Good Girl Stiletto conquers new heights with a stunning red-lacquered interior—a signature house shade and a symbol of passion, sophistication and beauty. Very Good Girl Eau de Parfum by Carolina Herrera takes you on a surprising olfactive journey, starting with top notes of playfully mischievous redcurrant and exotic lychee, leading to a seductive heart of rose. Vetiver and vanilla base notes provide a surprising and contemporary finish. Fragrance Notes: Top: Red Currant & Lychee Heart: Rose & Lilly Base: Vanilla Bourbon & Vetiver Size: 30ml, 50ml

GBP 75.00
1

Women Architects in the Modern Movement

Women Architects in the Modern Movement

Women Architects in the Modern Movement rewrites the history of modern architecture to elevate the often-overlooked female architects who helped build the movement. Starting with a theoretical analysis that situates women’s roles both in society and architecture specifically Carmen Espegel examines the transition from women as objects to subjects at the advent of modernity. This theoretical basis is grounded through four case studies on pioneering women architects: Eileen Gray Lilly Reich Margarete Schütte-Lihotzky and Charlotte Perriand. Along with illuminating their lives and work Espegel aims to help us examine and observe the world from a perspective where the feminine and masculine are not exclusive so that we might learn from the past in order to build with dignity in the future. Translated from the original Spanish by Angela Giral.

GBP 52.99
1

Bayesian Applications in Pharmaceutical Development

Bayesian Applications in Pharmaceutical Development

The cost for bringing new medicine from discovery to market has nearly doubled in the last decade and has now reached $2. 6 billion. There is an urgent need to make drug development less time-consuming and less costly. Innovative trial designs/ analyses such as the Bayesian approach are essential to meet this need. This book will be the first to provide comprehensive coverage of Bayesian applications across the span of drug development from discovery to clinical trial to manufacturing with practical examples. This book will have a wide appeal to statisticians scientists and physicians working in drug development who are motivated to accelerate and streamline the drug development process as well as students who aspire to work in this field. The advantages of this book are: Provides motivating worked practical case examples with easy to grasp models technical details and computational codes to run the analyses Balances practical examples with best practices on trial simulation and reporting as well as regulatory perspectives Chapters written by authors who are individual contributors in their respective topics Dr. Mani Lakshminarayanan is a researcher and statistical consultant with more than 30 years of experience in the pharmaceutical industry. He has published over 50 articles technical reports and book chapters besides serving as a referee for several journals. He has a PhD in Statistics from Southern Methodist University Dallas Texas and is a Fellow of the American Statistical Association. Dr. Fanni Natanegara has over 15 years of pharmaceutical experience and is currently Principal Research Scientist and Group Leader for the Early Phase Neuroscience Statistics team at Eli Lilly and Company. She played a key role in the Advanced Analytics team to provide Bayesian education and statistical consultation at Eli Lilly. Dr. Natanegara is the chair of the cross industry-regulatory-academic DIA BSWG to ensure that Bayesian methods are appropriately utilized for design and analysis throughout the drug-development process. | Bayesian Applications in Pharmaceutical Development

GBP 44.99
1

Process Chemistry in the Pharmaceutical Industry Volume 2 Challenges in an Ever Changing Climate

Process Chemistry in the Pharmaceutical Industry Volume 2 Challenges in an Ever Changing Climate

As pharmaceutical companies strive to develop safer medicines at a lower cost they must keep pace with the rapid growth of technology and research methodologies. Defying the misconception of process chemistry as mere scale-up work Process Chemistry in the Pharmaceutical Industry Vol. 2: Challenges in an Ever Changing Climate explores novel applications of synthetic physical and analytical chemistry in drug discovery and development. It offers an accurate depiction of the most up-to-date process research and development methods applied to synthesis clinical trials and commercializing drug candidates. The second installment in this progressive series this volumereviews the latest breakthroughs to advance process chemistry including asymmetric synthesis crystallization morphology enzymatic intervention green chemistry macromolecules (monoclonal antibodies biological molecules polymers) enantioselectivity organometallic chemistry process analytical tools chemical engineering controls regulatory compliance and outsourcing/globalization. It explores new approaches to synthetic processes examines the latest safety methods and experiment design and suggests realistic solutions to problems encountered in manufacturing and process development. Significant topics include atom economy ease of synthesis instrumentation automization quality control cost considerations green practices and future trends. Jointly edited by the founder/president of Delphian Pharmaceuticals and the director of Chemical R&D at Pfizer this book brings together contributions byreputed scientists technologists engineers and professors from leading academic institutions such as the Imperial College UK the University of Tokyo ETH Switzerland the International University at Bermen Germany and the University of Connecticut USA and from principal pharmaceutical companies that include Merck Bristol Myers Squibb Pfizer Novartis Eli Lilly Astrazeneca and DSM. | Process Chemistry in the Pharmaceutical Industry Volume 2 Challenges in an Ever Changing Climate

GBP 44.99
1